Loading…
ICMR-National Institute of Cancer Prevention and Research (NICPR) validated SHetA2, an oral small-molecule therapy, for further development in India.
SHetA2 targets the HPV E6 and E7 oncoproteins, which interfere with tumour-suppressor proteins p53 and Rb.
It is designed for pre-cancerous and cancerous cervical lesions, not for preventing initial HPV infection, and has been transferred to Emcure Pharmaceuticals for larger human trials in India.
In the US, an FDA-allowed Investigational New Drug application (IND 156700) and an open Phase 1 trial (NCT04928508) cover advanced ovarian, cervical, and endometrial cancers.
HPV's E6 and E7 oncoproteins interfere with the tumour-suppressor proteins p53 and Rb, which normally regulate cell-cycle control and programmed cell death. By targeting these oncoproteins, SHetA2 aims to prevent HPV-infected cells from becoming cancerous.
Simple Analogy: p53 and Rb act like a cell's 'brakes' — HPV's E6/E7 proteins cut the brake lines, and SHetA2 aims to stop that from happening.
GS Paper III > Science & Technology, Health
Which of the following bacteria is responsible for causing "Typhoid"?
Answer: Salmonella typhi
A tumour-suppressor protein that regulates DNA repair and apoptosis
A precancerous condition of the cervix, graded CIN 1 to CIN 3